3.2. Pharmacokinetics
The pharmacokinetics of taxol has been studied extensively against lung, breast, and ovarian cancers. Taxol is administered in patients through the intravenous route with the use of a formulation vehicle (mainly Cremophor® EL) for drug entrapment in micelles (Alex et al., 2005; Alves et al., 2018; Shin et al., 2018). The dose of taxol stated differently in various studies ranging from 105-270 mg/m2 in humans. The formulation vehicle not only affects the disposition of taxol but also influences the non-linear pharmacokinetics of taxol, specifically at a higher dosage. Plasma and urine samples were collected for estimation of taxol concentration through HPLC (Ishikawa et al., 2018). Analysis of blood samples from patients depicts clearance of this drug in approximately 3 hours, depending on the dose and vehicle used.